Stock Research: Bachem

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Bachem

SWX:BANB CH1176493729
40
  • Value
    94
  • Growth
    25
  • Safety
    Safety
    32
  • Combined
    60
  • Sentiment
    27
  • 360° View
    360° View
    40
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Bachem Holding AG is a biochemical company providing services to the pharmaceutical and biotechnology industries. It focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs). It operates under the Bachem and Clinalfa brands. The company operates in Switzerland and the United States. In the last fiscal year, the company had a market cap of $5,320 million, profits of $201 million, and revenue of $667 million, with 2207 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bachem are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Bachem. The only rank that is above average is the consolidated Safety Rank at 94, which means that the company has a financing structure that is safer than those of 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 32, which means that the share price of Bachem is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 25, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 27, which means that professional investors are more pessimistic about the stock than for 73% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
SDG 12
SDG 3
SDG 4
SDG 8
SPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 47 45 35
Growth
25 24 83 99
Safety
Safety
94 100 98 90
Sentiment
27 75 13 12
360° View
360° View
40 85 82 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
9 5 1 17
Opinions Change
50 62 75 26
Pro Holdings
n/a 80 53 72
Market Pulse
42 87 4 38
Sentiment
27 75 13 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 47 45 35
Growth
25 24 83 99
Safety Safety
94 100 98 90
Combined
60 78 100 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
18 33 30 11
Price vs. Earnings (P/E)
18 13 17 28
Price vs. Book (P/B)
44 40 37 13
Dividend Yield
61 72 63 61
Value
32 47 45 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
89 75 80 75
Profit Growth
25 42 56 78
Capital Growth
21 11 95 86
Stock Returns
29 37 35 95
Growth
25 24 83 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
94 95 96 49
Refinancing
57 60 59 96
Liquidity
98 100 100 96
Safety Safety
94 100 98 90

Similar Stocks

Discover high‑ranked alternatives to Bachem and broaden your portfolio horizons.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Ipsen

ENXTPA:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.